I know it is Tuesday but here is my Monday Morning Quarteback. It struck me a few days ago that Don stated that the cost of BoM2 to RVX is going to be $20 million. This is a very small amount of money in biotech and it should be very easy to raise given Breakthrough Designation by the FDA, CKD findings, PAH findings, preliminary independent Covid research findings, HIV and the list goes on.

For an example of raising financing consider Repare Therapeutics.

Prior to it’s IPO around June 19, 2020 Repare had already raised $147.5 million. And they were not even at a clinical trial stage!

• Private Capital Journal – June 1, 2020 - Repare Therapeutics has raised US $147.5 million. Major investors including Versant Ventures (30.1% pre-ipo), MPM Capital (21.0%), OrbiMed (11.2%), Cowen Healthcare Investments (9.2%), Fonds de solidarité FTQ (7.5%), Redmile Group (6.8%), BVF Partners, Logos Capital, Celgene/Bristol Myers Squibb, and Amplitude Ventures.

Note that there are no Saudi Princes in the Repare list…nor trips to Africa.

It has been 2 years and 7 months since BoM results were announced and management has achieved nothing on the financing side of the business. Precious time squandered.

Monday Morning Quarterback

I was excited about the go it alone strategy based on a successful Covid trial and supported downstream by Eversana, but, it appears that these trials have been completely botched every inch of the way. We were probably not given the name of the CRO because RVX being in a constant state of financial uncertainty had to hire the cheapest CRO in the market.

For the past 2 years we’ve been treated with a litany of misleading forward looking statements.

I agree with Nextblockbuster. It should be completely unacceptable for retail shareholders to be treated with such disrespect. There are very serious problems with this management team. Change needs to happen.

Still hoping and long.

Toinv